Aktis Oncology Raises $318 Million in Upsized U.S. IPO
Aktis Oncology, a cancer drug developer, completed its U.S. IPO, raising $318 million by pricing shares at $18 each. The upsized offering reflects strong investor demand, positioning the company for growth.
Insights:
Aktis Oncology Inc , a prominent player in the cancer drug development sector, has successfully completed its initial public offering (IPO) in the United States, marking a significant milestone for the company. On January 8, 2026, the company priced its upsized IPO at $18 per share, resulting in a capital raise of approximately $318 million. This strategic financial move positions Aktis Oncology with a targeted valuation of up to $945.4 million, underscoring the robust investor confidence in its potential.
